Letter : Kidney patients missing out
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: It is not only patients with haemophilia who are denied recombinant medication because of its expense ("Is it too much to ask that children with haemophilia get the best and safest treatment?", 23 September).
A significant proportion of patients with chronic renal failure also suffer with a severe anaemia that can be treated with recombinant human erythropoietin. This drug has the potential to greatly improve the health and quality of life of a lot of patients with renal failure, but it is also expensive, and its use is therefore being restricted in some areas.
As with recombinant Factor VIII, this is not experimental medicine we are addressing here, but safe, tried and tested medication that we would all want our patients or loved ones to have. Action is needed.
Dr PADDY GIBSON
Edinburgh
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments